Neurology

Florence-based Menarini Group has announced a USD667 million acquisition of the Stemline Therapeutics, an oncology-focused company. As per the agreement, Menarini plans to help Stemline to build a strong foothold in the U.S., and will also continue the development of Elzonris, a CD123 targeted therapy. The therapy had received FDA recommendation in 2018 as the first-ever approved treatment for blastic plasmacytoid dendritic cell neoplasm. After the announcement, the shares of Stemline therapeutics rose over 153%. Moreover, the company also plans to support Stemline in the launch of Elzonris, through its manufacturing hubs, in Europe and other emerging ma...